Archive for June, 2021
Aducanumab, a new drug to treat Alzheimer’s disease was recently given accelerated approval by the United States Food and Drug Administration. Developed by the US biotechnology company Biogen, aducanumab which will be commercially known as Aduhelm is first ever drug that targets the underlying cause of Alzheimer’s disease. Aducanumab is an antibody which targets and lowers a toxic protein […]